Loxapine (succinate)

Loxapine succinate is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppresses bacterial efflux pump activity and inhibit intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages[1][4][6].

Product Specifications

CAS Number

[27833-64-3]

UNSPSC

12352005

Hazard Statement

H301, H319

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Loxapine-succinate.html

Concentration

10mM

Purity

98.84

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 2.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)CCC(O)=O.CN1CCN(C2=NC3=CC=CC=C3OC4=CC=C(Cl)C=C24)CC1

Molecular Formula

C22H24ClN3O5

Molecular Weight

445.90

Precautions

H301, H319

References & Citations

[1]Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21 (1) :29-35.|[2]Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15 (1) :23-30.|[3]Lee T, et al. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12 (4) :277-85.|[4]Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013 Jun;27 (6) :479-89.